NCT03254667Enrolling by invitation
LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care
Source: ClinicalTrials.gov · Last updated 16 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 3500 (estimated)
- First submitted
- 15 Aug 2017
- Start date
- 25 Jul 2017
- Primary completion date
- 10 Nov 2030
- Lead sponsor
- Bausch Health Americas, Inc.
- Diseases
- Psoriasis
- NCT number
- NCT03254667
What you commit to
- Study type: Observational
- Planned participants: 3500
- From 25 Jul 2017 to the primary completion date, 10 Nov 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The subject is participating or planning to participate in a clinical trial with a non-marketed or marketed investigational drug (i.e. Phase I-IV drug trial).
- The subject is restarting the eligible medication less than 12 months since receiving the last dose.
Other
- The subject is unable or unwilling to provide informed consent to participate in the registry.
Who the study is looking for
- Diagnosis and main criteria for inclusion: a subject must have moderate to severe psoriasis diagnosed by a dermatologist
- Must be at least 18 years of age or older
- Started on or switched to a systemic psoriasis treatment within the previous 12 months. FDA-approved biologic treatments and select non-biologic treatments (eg, methotrexate, cyclosporine, or apremilast only) are permitted.
Age in the registry: 18 years to 99 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Registry Coordinator of this site? Confirm its status | Bridgewater | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.